Besponsa

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical* ❑ *Home* ❑ *Inpatient Hospital* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office* ❑ *Pharmacy*

What is the ICD-10 code? _____

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

 Besponsa SGM 2261-A – 11/2024.

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com

Criteria Questions:

1. What is the diagnosis?

❒ Acute lymphoblastic leukemia (ALL), *Continue to 2*

❒ Other, please specify. _____, *Continue to 2*

2. Is the patient currently receiving treatment with the requested drug?
❒ Yes, *Continue to 3*
❒ No, *Continue to 5*

3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?
❒ Yes, *Continue to 4*
❒ No, *Continue to 4*

4. How many cycles of the requested drug has the patient received?
_____cycles, *No further questions*

5. Does the patient have B-cell precursor acute lymphoblastic leukemia (ALL)?
❒ Yes, *Continue to 6*
❒ No, *Continue to 6*

6. Is the tumor CD22-positive as confirmed by testing or analysis to identify the CD22 protein on the surface of the B-cell? ***ACTION REQUIRED***: If Yes, attach chart note(s) or test results confirming CD22 protein on the surface of the B-cell.

❒ Yes ***ACTION REQUIRED****: Submit supporting documentation, Continue to 7*

❒ No, *Continue to 7*

❒ Unknown, *Continue to 7*

7. Will the patient receive more than 6 treatment cycles of the requested drug?
❒ Yes, *Continue to 8*
❒ No, *Continue to 8*

8. What is the clinical setting in which the requested drug will be used?

❒ Relapsed disease, *Continue to 9*

❒ Refractory disease, *Continue to 9*

❒ As frontline (induction) therapy, *Continue to 12*

❒ As consolidation therapy, *Continue to 14*

❒ Other, please specify. _____, *No further questions*

9. What is the Philadelphia chromosome status of the patient's disease?

❒ Philadelphia chromosome-positive disease, *Continue to 10*

❒ Philadelphia chromosome-negative disease, *Continue to 11*

❒ Unknown, *No further questions*

10. What is the requested regimen?

❒ The requested drug will be used as a single agent, *No further questions*

❒ The requested drug will be used in combination with cyclophosphamide, dexamethasone, vincristine, methotrexate, and cytarabine with or without blinatumomab, *No further questions*
❒ The requested drug will be used in combination with a tyrosine kinase inhibitor (e.g., imatinib, dasatinib, nilotinib, bosutinib, ponatinib), *No further questions*

❒ Other, please specify. _____, *No further questions*

11. What is the requested regimen?

❒ The requested drug will be used as a single agent, *No further questions*
❒ The requested drug will be used in combination with cyclophosphamide, dexamethasone, vincristine, methotrexate, and cytarabine with or without blinatumomab, *No further questions*

❒ Other, please specify. _____, *No further questions*

12. What is the Philadelphia chromosome status of the patient's disease?

❒ Philadelphia chromosome-positive disease, *Continue to 13*

❒ Philadelphia chromosome-negative disease, *Continue to 13*

13. What is the requested regimen?
❒ The requested drug will be used in combination with cyclophosphamide, dexamethasone, vincristine, methotrexate and cytarabine with or without blinatumomab, *No further questions*

❒ Other, please specify. _____, *No further questions*

14. What is the Philadelphia chromosome status of the patient's disease?

❒ Philadelphia chromosome-positive disease, *Continue to 15*

❒ Philadelphia chromosome-negative disease, *Continue to 16*

❒ Unknown, *No further questions*

15. What is the requested regimen?
❒ The requested drug will be used in combination with a tyrosine kinase inhibitor (e.g., imatinib, dasatinib, nilotinib, bosutinib, ponatinib, *No further questions*

❒ Other, please specify. _____, *No further questions*

16. What is the requested regimen?

❒ The requested drug will be used as a single agent, *No further questions*
❒ The requested drug will be used in combination with cyclophosphamide, dexamethasone, vincristine, methotrexate and cytarabine with or without blinatumomab, *No further questions*

❒ Other, please specify. _____, *No further questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com